Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors

Abstract excerpt

Omicron and its subvariants have rendered most authorized monoclonal antibody-based treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ineffective, highlighting the need for biologics capable of overcoming SARS-CoV-2 evolution. These mostly ineffective antibodies target variable epitopes. Here we describe broad-spectrum SARS-CoV-2 inhibitors developed by tethering the SARS-CoV-2 receptor,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Computational Drug Discovery Methods
• Share to SARS-CoV-2 and COVID-19 Research
• Share to Viral gastroenteritis research and epidemiology